logo
Mini-Invasive Surgery Eases Hemorrhoid Pain Fast

Mini-Invasive Surgery Eases Hemorrhoid Pain Fast

Medscape11-07-2025
At a recent session of the National Academy of Surgery, experts highlighted that minimally invasive techniques are playing an increasingly central role in proctologic surgery. Béatrice Vinson-Bonnet, MD, visceral and digestive surgeon at Poissy-Saint-Germain-en-Laye Community Hospital, noted that treatment for hemorrhoidal disease has advanced significantly, moving away from traditional hemorrhoidectomy toward less invasive, technology-driven procedures.
'Thanks to advances in technology, all surgical approaches now aim to be as minimally invasive as possible,' said Vinson-Bonnet. 'However, before considering surgery, we prioritize medical treatment for hemorrhoidal disease — addressing intestinal transit disorders, particularly constipation, and educating patients on proper bowel habits.' Surgery is considered only when these measures fail to provide relief.
Until the 2000s, hemorrhoidectomy was the primary surgical treatment for hemorrhoidal disease. Since then, less painful alternatives have emerged, including nerve blocks and stapling all designed to avoid external incisions and reduce postoperative pain and recovery times.
One such option is the pudendal nerve block, which involves anesthetizing the pudendal nerve using a long-acting agent. This provides 12-24 hours of postoperative pain relief following hemorrhoid surgery. However, stool passage over the surgical site can still cause significant discomfort between days 3 and 10, and complete healing may take 6 weeks, Vinson-Bonnet noted.
In 1998, Antonio Longo, MD, colorectal surgeon from Italy, and director of the European Centre for Coloproctology and Pelvic Diseases in Vienna, Austria, introduced stapled hemorrhoidopexy. This surgical technique uses a circular stapler to remove a circumferential ring of rectal mucosa above the hemorrhoids, repositioning prolapsing internal hemorrhoids to their normal anatomical position.
'Although innovative, stapled hemorrhoidopexy has been linked to serious complications and is now often replaced by a simpler technique that uses an anoscope to locate and ligate small rectal arteries,' said Vinson-Bonnet.
According to Vinson-Bonnet, these techniques are limited to internal hemorrhoids and are not appropriate for large external hemorrhoids and do not allow the removal of large external hemorrhoids, often caused by thrombosis, particularly after childbirth in women. Another drawback is recurrence, with symptoms returning to up to 20% of patients within 2 years.
'Thermofusion, which uses microwave energy to completely dry out internal bleeding, is an emerging technique. While still under evaluation, it is already being used in clinical practice,' she added. 'Other recent methods, such as radiofrequency — and, more rarely, laser — are also employed,' said Vinson-Bonnet.
Professor Émilie Duchalais, MD, PhD, digestive surgeon at Nantes University Hospital in Nantes, France, presented recent developments in minimally invasive treatment for fecal incontinence. She leads clinical and translational studies on this condition at the Institute of Digestive System Diseases.
'Sacral neuromodulation and Botox are two techniques mainly reserved for patients with fecal incontinence,' Duchalais explained. These are considered second- or third-line treatment options and are used only when medical treatment or rehabilitation has failed.
Sacral neuromodulation involves stimulating nerve roots near the sacrum, which engage in sphincter control and rectal sensitivity. 'Five to 10 years after implantation, long-term improvement is seen in 50%-70% of patients,' said Duchalais.
A major advantage of this method is that it allows a trial phase. Electrodes are temporarily implanted at the targeted site, enabling patients to evaluate the effectiveness of the treatment over 2-3 weeks. 'If the patient experiences at least a 50% reduction in incontinence episodes during this period, the device is permanently implanted. The system, similar to a pacemaker but placed in the buttocks, typically remains in place for at least 5 years, depending on the battery life,' she said.
'Urologists commonly use Botox to treat overactive bladder. Botox works by blocking acetylcholine, preventing muscle contractions, and reducing urinary leakage. In the rectum, Botox has a similar effect — blocking muscle activity and nerve signals to improve control in patients with fecal incontinence,' Duchalais noted.
Although effective, Botox provides only temporary relief. 'Its effects typically last 6-9 months. However, a recent study showed that after 5 years, patients required injections only once every 3 years on average,' she added.
Another approach currently under investigation is fat injection. 'Researchers are studying autologous fat injection into the anal sphincter as a potential treatment for urge incontinence. The technique aims to restore sphincter tone by harnessing the regenerative potential of stem cells found in fat tissue.' A clinical trial led by Rennes University Hospital, Rennes, France, is evaluating this method, and the early findings are promising. However, this approach remains experimental,' said Duchalais.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Cat dementia is similar to human Alzheimer's disease ...Tech & Science Daily podcast
Cat dementia is similar to human Alzheimer's disease ...Tech & Science Daily podcast

Yahoo

time2 days ago

  • Yahoo

Cat dementia is similar to human Alzheimer's disease ...Tech & Science Daily podcast

Listen here on your chosen podcast platform. Cats develop dementia similarly to humans with Alzheimer's disease. Scientists hope their findings lead to new treatments for both humans and our feline friends. For more, we spoke to the lead author, Dr Robert McGeachan, at the University of Edinburgh's Royal School of Veterinary Studies. A swarm of jellyfish forced the shutdown of France's largest nuclear power plant, Gravelines. But how unusual is this event? And, Reddit blocks the Internet Archive's Wayback Machine from archiving large portions of its site. Also in this episode: -How blowing through a conch shell could alleviate the symptoms of obstructive sleep apnoea -Lola Young urges Keir Starmer to block Rosebank oil and gas development projects -Natalie the Nerd builds a transparent GameBoy Colour

Electrophysiology Market worth US$21.72 billion by 2030 with 11.6% CAGR
Electrophysiology Market worth US$21.72 billion by 2030 with 11.6% CAGR

Yahoo

time3 days ago

  • Yahoo

Electrophysiology Market worth US$21.72 billion by 2030 with 11.6% CAGR

DELRAY BEACH, Fla., Aug. 15, 2025 /PRNewswire/ -- The global Electrophysiology Market, valued at US$11.41 billion in 2024, stood at US$12.55 billion in 2025 and is projected to advance at a resilient CAGR of 11.6% from 2025 to 2030, culminating in a forecasted valuation of US$21.72 billion by the end of the period. The rise of the electrophysiology market can be attributed to several drivers: the increasing prevalence of cardiovascular diseases, including arrhythmias and atrial fibrillation; patients and healthcare providers are increasingly favoring minimally invasive procedures over traditional surgical interventions; electrophysiological techniques, such as catheter ablation, offer less invasive options for treating certain cardiac arrhythmias; and government support and initiatives aimed at improving healthcare infrastructure and funding research and development in electrophysiology also contribute to market growth. Download PDF Brochure: Browse in-depth TOC on "Electrophysiology Market" 322 - Tables62 - Figures330 - Pages By product, in 2024, electrophysiology ablation catheters are expected to be the leading segment in the medical device market. This anticipated growth is largely driven by the rising global prevalence of atrial fibrillation (AF) and various cardiac arrhythmias, which has increased the demand for minimally invasive ablation techniques. Recent technological advancements in catheter design, such as the introduction of contact force-sensing mechanisms, irrigated-tip designs, and high-power short-duration (HPSD) ablation systems, have greatly enhanced procedural safety, precision, and clinical outcomes. These innovations are contributing to wider acceptance and increased utilization of these catheters within the medical community. By indication, the electrophysiology market, divided by medical indications, includes segments such as atrial fibrillation, atrial flutter, and atrioventricular nodal reentry tachycardia. Atrial flutter, characterized by rapid heartbeats from the atria, is increasingly common, especially among the elderly, due to age-related cardiac changes. This rising prevalence has created a demand for advanced diagnosis and treatment options tailored to atrial flutter. Innovations in catheter ablation, advanced imaging techniques, and new pharmacological therapies reflect the urgency for effective arrhythmia management in an aging population. By geography, in 2024, North America, primarily the US and Canada, is set for significant growth in the medical technology market. The region is a global leader in medical innovations, especially in electrophysiology, often adopting breakthroughs ahead of others. With some of the highest healthcare spending globally, the US influences the uptake of advanced medical technologies, enhancing patient outcomes and operational efficiency. Strong A investment in research and development fosters innovation and creates a robust marketplace for new products and services, solidifying North America's role as a key driver of growth in the medical technology sector. Request Sample Pages : As of 2024, prominent players in the electrophysiology market are Johnson & Johnson Services, Inc. (US), Abbott (US), Medtronic (Ireland), Koninklijke Philips N.V. (Netherlands), GE Healthcare (US), Boston Scientific Corporation (US), Japan Lifeline Co., Ltd (Japan), Stereotaxis, Inc. (US), MicroPort Scientific Corporation (China), and BIOTRONIK (Germany). Abbott (US): Abbott Laboratories is a comprehensive healthcare company that operates across diverse sectors, including pharmaceuticals, medical devices, diagnostics, and nutrition. The company has established a significant presence in electrophysiology, particularly in the development of advanced medical devices for cardiac electrophysiology procedures. Abbott's portfolio in this specialized market includes sophisticated mapping systems, electrophysiology catheters, and related technologies designed for the precise diagnosis and management of cardiac arrhythmias. Furthermore, Abbott is likely engaged in ongoing research and development initiatives aimed at innovating and enhancing electrophysiological technologies to improve patient outcomes and procedural efficiencies. Koninklijke Philips N.V. (Netherlands) Koninklijke Philips N.V. Philips, a Netherlands-based multinational company, is a significant player in the healthcare sector, particularly within medical technology. The company develops an extensive range of products that enhance capabilities in cardiology, patient monitoring, diagnostic imaging, and electrophysiology. In the electrophysiology domain, Philips offers advanced solutions aimed at the identification and management of cardiac arrhythmias. This product suite includes high-precision imaging technologies, advanced mapping systems, and specialized electrophysiology catheters, all essential tools utilized by cardiology professionals. Key offerings include the EP WorkMate system, which serves as a comprehensive electrophysiology recording and reporting platform, facilitating efficient data capture and analysis during procedures. Additionally, Philips has introduced state-of-the-art X-ray imaging systems designed for enhanced visualization during electrophysiological interventions. The EP Navigator and EP-XT Mapping system are also part of their innovative portfolio, providing clinicians with advanced three-dimensional mapping capabilities that improve procedural accuracy and patient outcomes. For more information, Inquire Now! Related Reports: Defibrillator Market Cardiac Monitoring & Cardiac Rhythm Management Devices Market Ablation Technology Market Catheters Market Digital X-ray Market Get access to the latest updates on Electrophysiology Companies and Electrophysiology Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets

GLP-1 Receptor Agonists Improve HS in Patients With Obesity
GLP-1 Receptor Agonists Improve HS in Patients With Obesity

Medscape

time4 days ago

  • Medscape

GLP-1 Receptor Agonists Improve HS in Patients With Obesity

TOPLINE: Investigators reported that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) were associated with significant improvements in clinical severity, patient-reported outcomes, and weight in patients with hidradenitis suppurativa (HS) and obesity. METHODOLOGY: The retrospective multicenter cohort study evaluated 66 adults (median age, 46 years; 58% women) with HS who received semaglutide, dulaglutide, or liraglutide for at least 3 months, using data from eight French hospitals, between 2017 and 2024. Their median BMI was 39.4, and 86% of patients had diabetes; 45%, 32%, and 23% of patients had Hurley stages I, II, and III disease, respectively. Outcomes included HS-Physician's Global Assessment (HS-PGA), flare frequency, Numerical Rating Scale (NRS)-Pain, NRS-Suppuration, Dermatology Life Quality Index (DLQI), and BMI at 6 months. Median follow-up was 18.5 months. TAKEAWAY: At 6 months, 54% of patients had achieved at least one-point reduction in HS-PGA and 12% of patients demonstrated at least two-point reduction; flares were reduced in 60% patients. NRS-Pain scores decreased in 52% of patients, NRS-Suppuration scores decreased in 53% patients, and improved quality of life, based on DLQI scores, was observed in 50% patients at 6 months. Among 34 patients with stable HS treatment, all outcome measures showed statistically significant improvements at 6 months (P < .001). Median BMI decreased from 39.4 to 37.2 at 6 months. IN PRACTICE: 'GLP-1 RAs offer promise for patients with HS and obesity and potentially for patients without obesity through immunological effects,' the study authors wrote. 'Randomized clinical trials are warranted to confirm the role of GLP-1 RAs in HS management,' they added. SOURCE: The study was led by Louise Gouvrion, MD, Department of Dermatology, Rennes University Hospital in Rennes, France, and was published online on August 13 in JAMA Dermatology. LIMITATIONS: The retrospective design, concurrent use of diverse HS therapies, potential selection bias, and absence of glycemic and inflammatory biomarker data limit causal inference. DISCLOSURES: The authors did not disclose any funding information. Several authors reported receiving personal fees, conference invitations, nonfinancial support from AbbVie, Almirall, Amgen, Bristol Myers Squibb, Lilly, Janssen, LEO Pharma, MSD, Novartis, UCB, and others. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store